Landscapes / Companies

Eisai

Japan

FollowEvery new trial, moved date and filing, and a Monday email
Furthest along
5 approved
6 in Phase 2
Next date
lecanemab, Phase 2 trial completes
Drugs
15
in active trials · 48 in all
Trials
19 active
162 since 2021

Drugs15

DrugHow it worksPartnerStageNext dateDetails
Amyloid-beta protofibril antibody
Biogen
Approved 3 Dec 2026soonPhase 2 trial completes
Kinase inhibitor
Merck & Co.
Approved 22 Mar 2027Phase 2 trial completes
Microtubule inhibitor
Approved 31 Mar 2027Phase 1/2 trial completes
JAK inhibitor
Approved in Japan 30 Nov 2027Phase 4 trial completes
Donepezilnot checked
Cholinesterase inhibitor
Approved 6 May 2030Phase 1 trial completes
—
Phase 2 3 Dec 2026soonPhase 2 trial completes
—
Phase 2 14 Feb 2027Phase 2 trial completes
—
Phase 1/2 31 Mar 2027Phase 1/2 trial completes
E2007not checked
—
Phase 2 6 Apr 2027Phase 2 trial completes
—
Phase 2 5 Aug 2028Phase 2 trial completes
Monoclonal antibody
Phase 1/2 8 Aug 2030Phase 1/2 trial completes
—
Phase 1 22 Jul 2027Phase 1 trial completes
Tasurgratinibnot checked
Tyrosine kinase inhibitor
Phase 1 31 Aug 2027Phase 1 trial completes
—
Phase 1 6 May 2030Phase 1 trial completes
—
Phase 1 —

About

No active trial
33 other drugs
SEC filings
None: it does not file with the US SEC
Registry names
5 names in ClinicalTrials.gov
Sources
ClinicalTrials.gov updated 18 Nov 2026 Industry-sponsored drug trials since 2021

Follow Eisai

Following is part of Solo: you see every change to Eisai the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in